SynthesisThe Cochrane database of systematic reviews2022
Laser therapy for treating hypertrophic and keloid scars.
Synthesis in The Cochrane database of systematic reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 8 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Early scar-directed interventions for thyroidectomy scars: a systematic review and network meta-analysis.Frontiers in surgery · 2026Pooled it
- Therapeutic methods and effect on keloid and hypertrophic scars: a systematic review.Frontiers in medicine · 2026Pooled it
- A systematic review of comparative clinical trials on the efficacy, safety, and patient satisfaction of ablative and non-ablative laser therapies for atrophic, hypertrophic, and keloid scars.Lasers in medical science · 2025Pooled it
- Fighting Bleb Fibrosis After Glaucoma Surgery: Updated Focus on Key Players and Novel Targets for Therapy.International journal of molecular sciences · 2025Pooled it
- Local adjuncts to minimally invasive endoscopic interventions for benign laryngotracheal stenosis: a meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Pooled it
- Laser Therapy in Hypertrophic and Keloid Scars: A Systematic Review and Network Meta-analysis.Aesthetic plastic surgery · 2024Pooled it
- The Effect of Fat Grafting on Scars Hyperpigmentation: A Systematic Review and Meta-Analysis.Aesthetic plastic surgery · 2024Pooled it
- Laser therapy for treating hypertrophic and keloid scars.The Cochrane database of systematic reviews · 2022Pooled it
- Comparing Punch Excision Combined with Triamcinolone Acetonide and 5-Fluorouracil Injection and Manual Fractional Technology Combined with Triamcinolone Acetonide and 5-Fluorouracil Injection in Keloids: A Single-Blinded Randomized Clinical Trial.Aesthetic plastic surgery · 2026Trial
- Combination Therapy of Intense Pulsed Light and Fractional Carbon Dioxide Laser Versus Botulinum Toxin Type A in Post-thyroidectomy Scar Prevention: A Prospective, Randomized Controlled Trial.Aesthetic plastic surgery · 2026Trial
- Clinical observation on manual linear array technology (MLAT) with ultra-pulsed COLasers in medical science · 2025Trial
- Photoacoustic imaging-based assessment of vascular changes in scars: a retrospective analysis of factors influencing PDL treatment efficacy.Lasers in medical science · 2026Article
- Efficacy and Safety of Silicone Gel Plus Laser Therapy for Scar: A Systematic Review and Meta-analysis.Plastic and reconstructive surgery. Global open · 2026Article
- Comparative Efficacy of Combined Carbon Dioxide Fractional Laser and Pulse Dye Laser versus Monotherapy for Hypertrophic Scars: A Network Meta-Analysis of Randomized Controlled Trials.Aesthetic plastic surgery · 2026Review
- An integrated analysis of lactylation signature reveals PRDX1 as a therapeutic target of keloid pathogenesis.Scientific reports · 2026Article
- Targeting NRP1 in Endothelial Cells Facilitates the Normalization of Scar Vessels and Prevents Fibrotic Scarring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Combined Fractional COPlastic and reconstructive surgery. Global open · 2026Article
- Research Advances in Therapeutic Strategies and Drug Delivery Systems for Pathological Scars.Pharmaceutics · 2026Review
- Comprehensive Update on Keloid Management.Archives of plastic surgery · 2026Article
- Ultrasound-Guided Low-Level He-Ne Laser Therapy Following Acupotomy Release for Carpal Tunnel Syndrome: A Multicenter Retrospective Study.Journal of pain research · 2026Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic and keloid scars are common skin conditions resulting from abnormal wound healing. They can cause itching, pain and have a negative physical and psychological impact on patients' lives. Different approaches are used aiming to improve these scars, including intralesional corticosteroids, surgery and more recently, laser therapy. Since laser therapy is expensive and may have adverse effects, it is critical to evaluate the potential benefits and harms of this therapy for treating hypertrophic and keloid scars.
objectivesTo assess the effects of laser therapy for treating hypertrophic and keloid scars. SEARCH
methodsIn March 2021 we searched the Cochrane Wounds Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL EBSCO Plus and LILACS. To identify additional studies, we also searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies as well as reviews, meta-analyses, and health technology reports. There were no restrictions with respect to language, date of publication, or study setting. SELECTION CRITERIA: We included randomised controlled trials (RCTs) for treating hypertrophic or keloid scars (or both), comparing laser therapy with placebo, no intervention or another intervention. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies, extracted the data, assessed the risk of bias of included studies and carried out GRADE assessments to assess the certainty of evidence. A third review author arbitrated if there were disagreements. MAIN
resultsWe included 15 RCTs, involving 604 participants (children and adults) with study sample sizes ranging from 10 to 120 participants (mean 40.27). Where studies randomised different parts of the same scar, each scar segment was the unit of analysis (906 scar segments). The length of participant follow-up varied from 12 weeks to 12 months. All included trials had a high risk of bias for at least one domain: all studies were deemed at high risk of bias due to lack of blinding of participants and personnel. The variability of intervention types, controls, follow-up periods and limitations with report data meant we pooled data for one comparison (and only two outcomes within this). Several review secondary outcomes - cosmesis, tolerance, preference for different modes of treatment, adherence, and change in quality of life - were not reported in any of the included studies. Laser versus no treatment: We found low-certainty evidence suggesting there may be more hypertrophic and keloid scar improvement (that is scars are less severe) in 585-nm pulsed-dye laser (PDL) -treated scars compared with no treatment (risk ratio (RR) 1.96; 95% confidence interval (CI): 1.11 to 3.45; two studies, 60 scar segments). It is unclear whether non-ablative fractional laser (NAFL) impacts on hypertrophic scar severity when compared with no treatment (very low-certainty evidence). It is unclear whether fractional carbon dioxide (CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.